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Abbreviations 
 
ADP: adenosine-diphosphate 
AK: adenylate kinase 
BSO: buthionine sulfoximine 
CYP: cytochrome P450 
DMEM: Dulbecco’s Modified Eagle Medium 
DTNB: 5,5’-dithio-bis(2-nitrobenzoic acid) 
FCCP: trifluoromethoxy carbonylcyanide phenylhydrazone 
FCS: fetal calf serum 
GR: glutathione reductase  
GSH: glutathione (reduced) 
GSSG: glutathione (oxidized) 
KPE: potassium phosphate buffer 
MDMA: 3,4-methylenedioxymethamphetamine 
MDPV: 3,4-methylenedioxypyrovalerone 
O2-: superoxide 
OCR: oxygen consumption rate 
PBS: phosphate-buffered saline  
PCA: perchloric acid 
SRB: sulforhodamine B 
TMRM: tetramethylrhodamine methyl ester 
tGSH: glutathione (total) 
β-NADPH: β-nicotinamide adenine dinucleotide 2′-phosphate 
Δψm: mitochondrial membrane potential 
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Abstract 
Synthetic cathinones are a new class of psychostimulant substances. Rarely, 
they can cause liver injury but associated mechanisms are not completely elucidated. 
In order to increase our knowledge about mechanisms of hepatotoxicity, we 
investigated the effect of five frequently used cathinones on two human cell lines. 
Bupropion was included as structurally related drug used therapeutically. In HepG2 
cells, bupropion, MDPV, mephedrone and naphyrone depleted the cellular ATP 
content at lower concentrations (0.2 to 1 mM) than cytotoxicity occurred (0.5 to 2 
mM), suggesting mitochondrial toxicity. In comparison, methedrone and methylone 
depleted the cellular ATP pool and induced cytotoxicity at similar concentrations (≥2 
mM). In HepaRG cells, cytotoxicity and ATP depletion could also be demonstrated, 
but cytochrome P450 induction did not increase the toxicity of the compounds 
investigated. The mitochondrial membrane potential was decreased in HepG2 cells 
by bupropion, MDPV and naphyrone, confirming mitochondrial toxicity. Bupropion, 
but not the other compounds, uncoupled oxidative phosphorylation. Bupropion, 
MDPV, mephedrone and naphyrone inhibited complex I and II of the electron 
transport chain, naphyrone also complex III. All four mitochondrial toxicants were 
associated with increased mitochondrial ROS and increased lactate production, 
which was accompanied by a decrease in the cellular total GSH pool for naphyrone 
and MDPV. In conclusion, bupropion, MDPV, mephedrone and naphyrone are 
mitochondrial toxicants impairing the function of the electron transport chain and 
depleting cellular ATP stores. Since liver injury is rare in users of these drugs, 
affected persons must have susceptibility factors rendering them more sensitive for 
these drugs. 
 
Key words: New psychoactive substances, cathinones, liver injury, mitochondria, 
electron transport chain, ROS 
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1. Introduction 
In recent years, various synthetic cathinones (“bath salts”, research 
chemicals) with amphetamine-like properties have emerged on the illicit drug market 
and have become popular alternatives to classic stimulants among drug users 
(Baumann et al., 2013; Prosser and Nelson, 2012). Cathinone designer drugs are 
derivatives of cathinone (Fig. 1), a naturally occurring β-keto-amphetamine found in 
the leaves of the Catha edulis plant, and are chemically and pharmacologically 
similar to classic illicit stimulants (Baumann et al., 2012; Rickli et al., 2015; Simmler 
et al., 2013; Simmler et al., 2014). Therefore, the health risks posed by synthetic 
cathinones may be similar to the classic stimulants (Liechti, 2015). A rare, but 
potentially severe adverse reaction of stimulant use is hepatotoxicity (Andreu et al., 
1998; De Carlis et al., 2001; Ellis et al., 1996; Garbino et al., 2001; Jones et al., 
1994; Kamijo et al., 2002). Most research concerning stimulant hepatotoxicity has so 
far focused on 3,4-methylenedioxymethamphetamine (MDMA; “ecstasy”). However, 
the hepatotoxic mechanism of MDMA is currently not entirely understood and 
multiple factors including polydrug abuse, hyperthermia, and metabolism appear to 
be associated with liver injury in MDMA users (Antolino-Lobo et al., 2011b; Carvalho 
et al., 2012; Dias da Silva et al., 2013a; Dias da Silva et al., 2013b). In comparison, 
data on hepatotoxicity of the newly used synthetic cathinones is currently scarce. A 
case of acute liver failure after synthetic cathinones use has been described 
(Fröhlich et al., 2011) and in vitro studies showed that mitochondrial dysfunction and 
oxidative stress contribute to hepatic injury associated with these compounds 
(Valente et al., 2016a; Valente et al., 2016b). 
In the current study, we aimed to investigate in more detail the mechanisms 
of hepatocellular toxicity of several synthetic cathinones (Fig. 1) with a focus on 
mitochondrial toxicity. We therefore investigated the toxicity of the cathinone 
designer drugs 3,4-methylenedioxypyrovalerone (MDPV), 4-methylmethcathinone (4-
MMC; mephedrone), 4-methoxymethcathinone (4-MeOMC; methedrone), 3,4-
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methylenedioxymethcathinone (βk-MDMA; methylone), and naphthylpyrovalerone 
(naphyrone) in two human hepatocyte cell lines. In addition, we included bupropion, 
a synthetic cathinone used as an antidepressant and as a smoking cessation aid. 
 
 
2. Methods 
2.1. Test substances 
Naphyrone was synthesized as previously described by Meltzer et al. 
(Meltzer et al., 2006). Methylone, mephedrone, methedrone, and MDPV were 
purchased from Lipomed (Arlesheim, Switzerland) with HPLC purity of >98.5%. 
Bupropion was purchased from Cayman Chemicals (Ann Arbor, MI, USA), with a 
purity of >98%. All drugs were obtained as racemic hydrochloride salts. Drug stocks 
were made in autoclaved Milli-Q water and were freshly prepared for each assay.  
 
2.2. Cell line and culture 
The HepG2 cell line was obtained from the American Type Culture Collection 
(ATCC, Manassas, USA) and cultured in Dulbecco’s Modified Eagle Medium 
(DMEM, 1 g/l glucose) supplemented with 10% heat inactivated fetal calf serum 
(FCS), 10 mM HEPES buffer, 2 mM GlutaMAXTM, 1% MEM non-essential amino 
acids, and penicillin-streptomycin (10,000 U/ml corresponding to 10 mg/ml). Cell 
culture medium and supplements were purchased from Invitrogen (Basel, 
Switzerland).  
The HepaRG cell line was obtained from Biopredic International (Saint 
Grégoire, France) and cultured in William’s E medium (no glutamine) supplemented 
with 10% FCS, 2 mM L-glutamine, 50 µM hydrocortisone hemisuccinate (Sigma 
Aldrich, Buchs, Switzerland), 0.05% human insulin (9.5–11.5 mg/ml insulin, Sigma 
Aldrich), and penicillin–streptomycin (10,000 U/ml corresponding to 10 mg/ml). The 
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cells were cultured at 37 °C in a 5% CO2 humidified atmosphere and passaged using 
trypLETM Express reagent (Invitrogen) when they reached 70–80% confluency. 
 
2.3. Cytotoxicity of HepG2 cells 
Cytotoxicity was assessed with the ToxiLight BioAssay Kit from Lonza (Basel, 
Switzerland) and conducted according to the manufacturer’s manual. Briefly, 25,000 
HepG2 cells per well were seeded in a 96-well plate. The following day, the cells 
were treated with 100 µl of the test substances dissolved in medium (0.01 mM, 0.1 
mM, 1 mM, and 2 mM for each drug and additionally 0.2 mM and 0.5 mM for 
bupropion and naphyrone). Treatment with 0.5% Triton X-100 was used as a positive 
control. After 24 h, 50 µl of the ToxiLight assay buffer was added to 20 µl of 
supernatant and luminescence was measured with a Tecan M200 Pro Infinity plate 
reader (Männedorf, Switzerland) after 5 min incubation. The luminescence signal 
was then compared to medium control. 
 
2.4. ATP Content in HepG2 cells 
The ATP content was assessed with the CellTiter-Glo Luminescent Cell 
Viability Assay from Promega (Dübendorf, Switzerland) according to the 
manufacturer’s manual. Briefly, 25,000 HepG2 cells per well were seeded in a 96-
well plate and cultured overnight. The cells were then treated for 24 h with 100 µl of 
the test substances dissolved in medium (concentrations as for cytotoxicity). 
Treatment with 0.5% Triton X-100 was used as a positive control. Thereafter, 50 µl of 
the supernatant was discarded and 50 µl of CellTiter-Glo reagent was added to each 
well. The plate was then shaken for 15 min at room temperature to induce cell lysis. 
Thereafter, the luminescent signal was measured with a Tecan M200 Pro Infinity 
plate reader and compared with medium control. 
 
2.5. Cytotoxicity and ATP content in HepaRG cells 
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HepaRG cells were cultured and differentiated as follows. 10,000 cells per 
well were seeded in a 96-well plate and the growth medium was replaced with fresh 
medium every 3–4 days for 2 weeks. Thereafter, the medium was replaced with 
medium containing 2% of DMSO in order to differentiate the cells into cholangiocyte- 
and hepatocyte-like cells. The medium was again replaced with fresh medium every 
3–4 days for 2 weeks and finally replaced with medium containing no DMSO and 
only 2% FCS. After three days, the medium of some cell preparations was replaced 
with the same medium containing 20 µM rifampicin (Sigma Aldrich) every 24 h for 
cytochrome P450 (CYP) induction. The uninduced cell preparations were treated 
identically with medium not containing rifampicin. After 72 h, the cells were treated 
with the test drugs (0.01 mM, 0.1 mM 1 mM, and 2 mM), medium control or 0.5% 
Triton X-100. The treatment and experimental procedures were the same as 
described for HepG2 cells. 
 
2.6. Mitochondrial membrane potential 
The mitochondrial membrane potential (Δψm) can be regarded as a global 
indicator of mitochondrial function (Felser et al., 2013). Tetramethylrhodamine methyl 
ester (TMRM; Thermo Scientific, Wohlen, Switzerland) staining was used to measure 
Δψm. TMRM is a non-cytotoxic cationic red-orange fluorescent dye that permeates 
into the mitochondria. 150,000 HepG2 cells were cultured in a 24-well plate overnight 
and then treated for 24 h with 500 µl of medium containing the test drugs (0.01 mM, 
0.1 mM 0.2 mM, 0.5 mM, and 1 mM). The uncoupling agent trifluoromethoxy 
carbonylcyanide phenylhydrazone (FCCP, Sigma Aldrich) at a concentration of 9 µM 
served as a positive control. After treatment, the cells were washed with phosphate-
buffered saline (PBS, Invitrogen) and detached with 0.05% trypsin-EDTA (Invitrogen) 
at 37 °C. 500 µl medium were added to the wells and the content was then 
transferred into polypropylene tubes. The cells were centrifuged at 1500g for 2.5 min, 
washed with PBS and centrifuged again. The supernatant was removed and the cells 
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were re-suspended in PBS containing 100 nM TMRM. After 20 minutes of incubation 
at 37 °C in the dark, the cells were centrifuged at 300g for 5 min, re-suspended in 
300 µl PBS, and transferred into polypropylene microtubes. Fluorescence (FL-2) of 
10,000 live cells was measured with a FACSCalibur flow cytometer (Becton 
Dickinson, Allschwil, Switzerland). 
 
2.7. Cellular total glutathione content 
Glutathione is an important antioxidant agent; the cellular total glutathione 
(tGSH) pool consists of reduced (GSH) and oxidized (GSSG) glutathione. Oxidation 
of GSH is a defense mechanism against cellular stress and a decrease in the GSH 
content makes cells more vulnerable to toxic agents. The tGSH content was 
determined with the enzymatic recycling method described by (Rahman et al., 2006). 
The assay is based on the oxidation of GSH by 5,5’-dithio-bis(2-nitrobenzoic acid) 
(DTNB), which is reduced to the yellow 5’-thio-2-nitrobenzoic acid. Briefly, 750,000 
HepG2 cells per well were seeded in a 6-well plate and left to attach overnight. The 
following day, the cells were treated with 1 ml of test drugs dissolved in medium. 
After 24 h, the cells were washed twice with 1 ml of cold PBS and then harvested 
with 0.05% trypsin-EDTA. Culture medium was added, the cell suspension was 
transferred into pre-chilled polypropylene tubes, and centrifuged at 1000g and 4 °C 
for 5 min. The supernatant was discarded and the cells re-suspended in cold PBS. 
The cells were centrifuged again and re-suspended in 1 ml of cold extraction buffer 
(0.1% Triton X-100 and 0.6% sulfosalicylic acid in 0.1 M potassium phosphate buffer 
with 5 mM EDTA disodium salt, pH 7.5 [KPE]). After two freeze-thaw cycles, the cells 
were centrifuged at 3000g and 4 °C for 4 min and the supernatant was then 
immediately transferred into a fresh polypropylene tube. At this point, the cell extracts 
could be frozen at -80 °C until further use for up to 10 days. To measure tGSH, 20 µl 
of standards (0.103–26.4 µM GSH in KPE and blank) and 20 µl of the cell extracts 
were added to a 96-well plate. 100 µl of a DTNB-glutathione reductase (GR) solution 
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(2 mg DTNB and 10 µl of GR [9.5 mg protein/ml; 189 units/mg protein] in 6 ml KPE) 
were added to each well. After 30 seconds, 50 µl of a β-nicotinamide adenine 
dinucleotide 2′-phosphate (β-NADPH) solution (2 mg of β-NADPH tetrasodium salt 
hydrate in 3 ml of KPE) was added to each well. Immediately thereafter, the 
absorbance at 412 nm was measured with a Tecan M200 Pro Infinity plate reader 
every 0.5 min for 2 min. The protein content was determined with the Pierce Protein 
Assay Kit (Thermo Fisher) and the tGSH content was then adjusted to protein. 
 
2.8. Oxygen consumption 
The oxygen consumption rate (OCR) was measured with a Seahorse XF24 
extracellular flux assay kit (Seahorse Biosciences, North Billerica, MA, USA). 
100,000 HepG2 cells per well were seeded in a Seahorse XF24 cell culture 
microplate coated with poly-D-lysine. The following day, the cells were treated with 
the test drugs. After 24 h, the medium was removed and the cells were washed with 
unbuffered DMEM (4 mM L-glutamate, 1 mM pyruvate, 1 g/l glucose, 63.3 mM 
sodium chloride, pH 7.4), pre-warmed to 37 °C. Thereafter, unbuffered DMEM was 
added to the cells and the plate was incubated for 40 min at 37 °C in a CO2 free 
incubator. The ports of the XF24 assay cartridge were then loaded with oligomycin, 
FCCP, or rotenone in order to reach a final concentration of 1 µM for each of these 
compounds. The XF24 Assay cartridge was loaded into a Seahorse XF24 Analyzer 
(Seahorse Biosciences) and the program was run according to the instructions. The 
oxidative leak was determined after inhibition of the mitochondrial phosphorylation by 
oligomycin and the maximal respiration was determined after stimulation of the 
electron transport chain by FCCP. Extramitochondrial respiration was determined 
after complex I inhibition by rotenone and subtracted from basal, leak, and maximal 
respiration. The protein content was determined using sulforhodamine B (SRB) 
staining. The cells were fixed with 100 µl of 50% (w/v) trichloroacetic acid (TCA) 
added directly to the assay medium of each well. After incubation for 1 h at 4 °C, the 
10	  	  
cells were washed with deionized water and then stained with 0.4% (w/v, in 1% [v/v] 
acetic acid) SRB. After 20 min, the cells were rapidly washed with 1% (v/v) acetic 
acid and the incorporated dye was solubilized with 100 µl of 10 mM TRIS base. The 
absorbance was then measured at 490 nm. 
 
2.9. Activity of specific enzyme complexes of the mitochondrial electron transport 
chain 
The activity of specific enzyme complexes of the mitochondrial respiratory 
chain was analyzed using an Oxygraph-2k high-resolution respirometer equipped 
with DataLab software (Oroboros instruments, Innsbruck, Austria). HepG2 cells were 
treated with test drugs for 24 h and afterwards re-suspended in MiR05 (mitochondrial 
respiration medium containing 0.5 mM EGTA, 3 mM magnesium chloride, 20 mM 
taurine, 10 mM potassium dihydrogen phosphate, 20 mM HEPES, 110 mM sucrose, 
1 g/l fatty-acid free bovine serum albumin, and 60 mM lactobionic acid, pH 7.1). The 
cells were then transferred into the pre-calibrated Oxygraph chamber (Pesta and 
Gnaiger, 2012). Digitonin (10 µg/1 million cells) was used to permeabilize the cells. 
Complexes I and III were analyzed using L-glutamate and malate (10 and 2 mM, 
respectively) as substrates followed by the addition of adenosine-diphosphate (ADP; 
2.5 mM) and rotenone (0.5 µM) as an inhibitor of complex I. Duroquinol (0.5 mM) 
was then added as a substrate of complex III. Complexes II and IV were analyzed 
using succinate (10 mM) as substrate and rotenone (0.5 µM) as a complex I inhibitor, 
followed by the addition of ADP (2.5 mM). After the addition of the complex III 
inhibitor antimycin A (2.5 µM), N,N,N’,N’-tetramethyl-1,4-phenylendiamine and 
ascorbate (0.5 and 2 mM, respectively) were added to investigate complex IV 
activity. The absence of a stimulatory effect of exogenous cytochrome c (10 µM) on 
respiration confirmed integrity of the outer mitochondrial membrane. Protein content 
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was determined with the Pierce Protein Assay Kit. Respiration was expressed as 
oxygen consumption per mg protein. 
 
2.10. ROS production 
ROS production was determined with the red mitochondrial superoxide (O2-) 
indicator MitoSOX (Invitrogen) according to the manufacturer’s manual. MitoSOX red 
is a live-cell permeant fluorogenic dye that targets the mitochondria and exhibits red 
fluorescence upon oxidation by superoxide. The seeding and treatment conditions 
were the same as described for cytotoxicity and ATP assays with HepG2 cells; 
however, 50 µM amidarone was used as a positive control. Briefly, 100 µl of 
MitoSOX reagent (2.5 µM) were added to each well of the 96-well plate and 
incubated for 10 min at 37 °C in the dark. After that, the fluorescence was measured 
at 510/580 nm with a Tecan M200 Pro Infinity plate reader. The protein content was 
assessed with the Pierce Protein Assay Kit. 
 
2.11. Lactate Determination 
Lactate concentrations in the cell culture assay were determined with an 
enzymatic assay after protein precipitation (Olsen, 1971). Briefly, 50 µl of 
supernatant from the MitoSOX assay were diluted with 50 µl of 6% (v/v) perchloric 
acid (PCA), vortexed, and centrifuged at 3000g for 15 min. Reagent buffer consisting 
of 100 µl hydrazine buffer (6.8 mM EDTA, 100 mM hydrazine sulphate 1 M hydrazine 
hydrate, pH 9), 0.2 mg NAD+  (free acid; Roche diagnostics, Rotkreuz, Switzerland) 
and 1 µl LDH (5 mg/ml; Roche diagnostics) were added to 10 µl of sample in a 96-
well plate. After 30 min incubation at room temperature, the absorbance was 
measured and compared to a lactic acid standard curve. 
 
2.12. Statistics 
Data are presented as mean ± SEM and statistical analyses were performed 
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using GraphPad Prism 6 (GraphPad Software, La Jolla, CA, USA). The activity of the 
enzyme complexes of the mitochondrial electron transport chain was compared to 
vehicle control with an unpaired two-tailed Student's t-test. For the remaining assays, 
means were compared to control and differences between control and test drugs 
were calculated with ANOVA followed by Dunett’s test. P-values below 0.05 were 
considered statistically significant. 
 
 
3. Results 
3.1. Cytotoxicity and ATP content in HepG2 cells 
AK release and cellular ATP content were determined as markers for 
cytotoxicity and mitochondrial function, respectively. In HepG2 cells after 24 h of 
exposure, all cathinones were cytotoxic and decreased the cellular ATP content in a 
concentration-dependent manner (Fig. 2a-d; Fig. 3a, 3b; Table 1). Bupropion was 
cytotoxic starting at 2 mM while a decrease in ATP was observed already at 0.5 mM 
(Fig. 2a). For MDPV, we observed cytotoxicity starting at 2 mM and a decrease in 
ATP already at 1 mM (Fig. 2b). Mephedrone was cytotoxic starting at 2 mM and 
decreased ATP at 1 mM (Fig. 2c). Naphyrone was cytotoxic at 0.5 mM and 
decreased ATP levels at 0.2 mM (Fig. 2d). For methedrone, we observed cytotoxicity 
and a decrease in ATP content starting at 2 mM (Fig. 3a). Methylone was cytotoxic at 
2 mM without significant alteration in ATP content (Fig. 3b). In summary, a decrease 
in the cellular ATP content at non-cytotoxic drug concentrations, which is compatible 
with mitochondrial toxicity (Felser et al., 2013; Kamalian et al., 2015), was observed 
for bupropion, MDPV, mephedrone, and naphyrone. 
 
3.2. Cytotoxicity and ATP content in HepaRG cells 
HepaRG were less susceptible than HepG2 cells to the toxicants 
investigated. After 24 h of drug exposure, we observed cytotoxicity only for bupropion 
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and naphyrone and a decrease in ATP content additionally for MDPV (Fig. 2a, 2b, 
2d; Table 1). Bupropion was cytotoxic starting at 2 mM with a decrease in the ATP 
content at 1 mM (Fig. 2a). MDPV decreased ATP at starting 2 mM without being 
cytotoxic (Fig. 2b). For naphyrone, we observed cytotoxicity and a decrease in ATP 
content starting at 1 mM (Fig. 2d). As in HepG2 cells, bupropion and MDPV 
decreased ATP content at non-cytotoxic drug concentrations, underlining possible 
mitochondrial toxicity for these toxicants (Felser et al., 2013; Kamalian et al., 2015). 
Induction of drug-metabolizing enzymes with 20 µM rifampicin (Berger et al., 2016) 
prior to treatment with the toxicants did not cause a difference in cytotoxicity or 
decrease in the ATP content compared to non-induced cells (data not shown). Since 
CYP induction in HepaRG cells did not seem to play a major role in toxicity and 
HepG2 cells were more sensitive to the toxicants, we decided to continue our 
investigations in HepG2 cells only. 
 
3.3. Effect on mitochondrial membrane potential 
Next, we determined the effect of the synthetic cathinones on the 
mitochondrial membrane potential (Δψm) to further investigate a possible role of 
mitochondria in cellular ATP reduction. HepG2 cells treated for 24 h showed a 
decreased Δψm for bupropion, MDPV, and naphyrone (Fig. 4a, 4b, 4f). Bupropion 
reduced the Δψm starting at 0.5 mM (Fig. 4a), MDPV at 1 mM (Fig. 4b), and 
naphyrone at 0.2 mM (Fig. 4f). Mephedrone, methedrone, and methylone did not 
cause a decrease of Δψm at concentrations up to 1 mM (Fig. 4c, 4d, 4e). The 
uncoupler FCCP (9 µM) that we included as positive control reduced the Δψm by 
42% (data not shown). 
 
3.4. Effect on cellular oxygen consumption 
A decrease in cellular ATP and Δψm can be caused by impairment and/or 
uncoupling of the mitochondrial respiratory chain (Felser et al., 2013; Krähenbühl, 
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2001). We therefore assessed the effect of cathinones on the mitochondrial 
respiratory chain using a XF24 analyzer. Considering the observed decrease in the 
cellular ATP content at non-cytotoxic concentrations and/or decreased Δψm, we 
tested bupropion, MDPV, mephedrone, and naphyrone at various concentrations 
(Fig. 5a–d). Bupropion caused an increase in leak respiration at 0.8 mM (Fig. 5a), 
suggesting uncoupling of oxidative phosphorylation. Mephedrone decreased the 
basal respiration at 1 mM and the maximal respiration at 0.5 and 1 mM (Fig. 5c). 
Naphyrone decreased the maximal respiration at 0.05 mM, 0.1 mM, and 0.2 mM 
(Fig. 5d). MDPV decreased the maximal respiration as well, but without reaching 
statistical significance (Fig. 5b). 
As shown, methedrone and methylone neither decreased ATP at non-cytotoxic 
concentrations (Fig. 3a, 3b) nor did they disrupt Δψm (Fig. 4d, 4e). We therefore 
investigated the oxygen consumption of these substances only at the highest non-
cytotoxic concentration (1 mM) and we did not find any difference compared to 
control incubations (data not shown). 
We then determined the activity of the complexes of the mitochondrial electron 
transport chain for bupropion, MDPV, mephedrone, and naphyrone using a high-
resolution respiratory system (Fig. 6a–h). Bupropion (0.5 mM), MDPV (1 mM), and 
mephedrone (1 mM) inhibited complex I and complex II activity (Fig. 6a–f). At 0.2 
mM, naphyrone inhibited complex I, complex II, and complex III activity (Fig. 6g, 6h). 
 
3.5. Effect on lactate and ROS production and cellular GSH 
Depending on its extent, the inhibition of the electron transport chain can 
have several metabolic consequences. Cells try to compensate the loss of 
mitochondrial ATP production by increasing glycolysis, resulting in increased lactate 
concentrations in the supernatant, the end product of glycolysis (Felser et al., 2014). 
In addition, inhibition of complex I and complex III of the electron transport chain can 
stimulate intra-mitochondrial ROS production (Dröse and Brandt, 2012). 
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Accumulating superoxide anion is then metabolized by SOD2 to hydrogen peroxide, 
which can be reduced by gluthione peroxidase, leading to a decrease in reduced 
(GSH) and an increase in oxidized glutathione (GSSG). The cellular content of GSH 
is therefore a measure of oxidative stress (Rahman et al., 2006). Bupropion caused 
an accumulation of superoxide and lactate at 0.5 mM but without affecting cellular 
GSH (Fig. 7a). For MDPV, we detected increased lactate concentrations at 1 mM as 
well as increased superoxide levels which were accompanied by a decrease in GSH 
at 2 mM (Fig. 7b). Mephedrone stimulated lactate and superoxide production at 1 
mM without a significant decrease in GSH up to 2 mM (Fig. 7c). Naphyrone 
stimulated lactate and superoxide production already at 0.2 mM with a simultaneous 
decrease in GSH (Fig. 7d). Buthionine sulfoximine (BSO), which we used as a 
positive control, decreased GSH to 14.1 nmol per mg protein, which corresponds to 
an 83% decrease compared to control incubations (data not shown). 
 
 
4. Discussion 
Our investigations demonstrate that in HepG2 cells all cathinones 
investigated were cytotoxic and, except methylone, decreased the cellular ATP 
content in a concentration-dependent fashion. Bupropion, MDPV, mephedrone, and 
naphyrone decreased the cellular ATP content at lower concentrations than 
cytotoxicity occurred, compatible with mitochondrial toxicity. For these substances, 
impairment of the mitochondrial respiratory chain could be demonstrated directly 
and/or indirectly (mitochondrial ROS production and lactate production) at similar 
concentrations as ATP depletion. In HepaRG cells, the compounds investigated were 
less toxic than in HepG2 cells, but with a similar pattern concerning cytotoxicity and 
ATP depletion. CYP induction by rifampicin in HepaRG cells did not incease 
cytotoxcitiy or depletion of the ATP pool. Thus, more active metabolite formation by 
CYPs did not enhance toxicity. 
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Regarding CYP induction, it is however important to be aware that CYP2D6 
cannot be induced with rifampicin (Berger et al., 2016). CYP2D6 has been shown to 
be an important enzyme regarding the metabolism of synthetic cathinones (Helfer et 
al., 2015; Meyer et al., 2010; Negreira et al., 2015; Pedersen et al., 2013a; Pedersen 
et al., 2013b) and it is therefore possible that the production of toxic metabolites may 
have been missed. For instance, the catechol metabolite of MDMA which is formed 
by CYP2D6, appears to be more hepatotoxic than the parent compound (Antolino-
Lobo et al., 2011a; Carmo et al., 2006).  
In accordance with our results, a recently published study has also shown 
that HepaRG cells are quite resistant to cytotoxicity elicited by synthetic cathinones, 
with EC50 concentrations >2 mM and >5 mM for MDPV and methylone, respectively, 
determined through the MTT reduction assay (Valente et al., 2016a). We therefore 
also used HepG2 cells for our investigations, as they represent a good in vitro model 
for studying the effect of toxicants on mitochondrial function (Felser et al., 2013; 
Kamalian et al., 2015). In the current study, cytotoxicity was observed in HepG2 cells 
for all test drugs in a concentration-dependent manner, which, with the exception of 
methylone, was accompanied by ATP depletion. For bupropion, MDPV, 
mephedrone, and naphyrone, ATP depletion was observed at lower concentrations 
than cytotoxicity, suggesting mitochondrial dysfunction (Felser et al., 2013; Kamalian 
et al., 2015). For bupropion, MDPV, and naphyrone, ATP depletion was 
accompanied by a decrease in Δψm, further supporting the hypothesis that these 
compounds cause mitochondrial dysfunction. Since a decrease in Δψm can be due to 
impaired activity of the mitochondrial electron transport chain, we investigated the 
effects of the toxicants on oxidative metabolism of HepG2 cells in more detail. For 
bupropion, the cellular oxygen consumption in the presence of the complex I 
substrates L-glutamate and pyruvate revealed an increase in leak respiration, 
suggesting uncoupling of oxidative phosphorylation. For mephedrone, we observed a 
decrease in basal and maximal respiration and for naphyrone a decrease in maximal 
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respiration, compatible with inhibition of the electron transport chain. For MDPV, 
there was a numeric decrease in maximal respiration, which did not achieve 
statistical significance due to a high variation in the control samples. MDPV was 
associated with an increase in mitochondrial ROS production and cellular generation 
of lactate, both indirect markers of a decreased function of the mitochondrial electron 
transport chain and mitochondrial ATP production (Felser et al., 2013; Felser et al., 
2014). Using high-resolution respirometry, inhibition of complex I and II of the 
electron transport chain by bupropion, MDPV, mephedrone, and naphyrone and 
inhibition of complex III by naphyrone could be shown directly. In comparison, 
methedrone and methylone did not affect the enzyme complexes of the respiratory 
chain. Methedrone and methylone did not cause ATP depletion at non-cytotoxic 
concentrations either, nor did they alter Δψm or the cellular oxygen consumption at 1 
mM. For methedrone and methylone, effects on mitochondria can therefore most 
likely not explain cytotoxicity. 
The inhibition of complex I and III of the mitochondrial respiratory chain can 
be associated with increased mitochondrial ROS production (Dröse and Brandt, 
2012), which can lead to a reduction of the mitochondrial and cellular GSH stores 
and opening of the mitochondrial membrane permeability transition pore (Green and 
Reed, 1998). In the current study, increased ROS production was observed for all 
mitochondrial toxicants (bupropion, MDPV, mephedrone, and naphyrone), but a 
significant decrease in the cellular GSH pool was only detected for MDPV and 
naphyrone. In support of our results, MDPV has previously been shown to stimulate 
ROS and RNS production and to deplete the cellular GSH stores in primary rat 
hepatocytes (Valente et al., 2016b). 
A second consequence of the inhibition of the mitochondrial function is a shift 
in the ATP production from mitochondria to glycolysis with a concomitant increase in 
lactate production (Felser et al., 2014). As expected, the lactate concentration in the 
supernatant of the incubations containing one of the four compounds affecting 
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mitochondrial function increased significantly, paralleling the increase in ROS 
production (Fig. 7). 
Among the four compounds affecting mitochondrial function, bupropion has 
most often been associated with liver injury (Alonso Rodriguez et al., 2010; Alvaro et 
al., 2001; Carlos Titos-Arcos et al., 2008; Hu et al., 2000; Humayun et al., 2007; 
Khoo et al., 2003). The results of the current study suggest that this may more likely 
be due to the broad use of this compound as a drug than due to a more pronounced 
mitochondrial toxicity compared to the other cathinones investigated. Bupropion was 
the only compound, however, that not only inhibited complex I and II of the electron 
transport chain, but also uncoupled oxidative phosphorylation, which may increase 
its toxicity. 
For all compounds investigated, hepatic toxicity is a rare, but potentially life-
threatening event. Certain factors may therefore increase the probability to develop 
liver injury when ingesting these compounds. One of these factors is the dose, as 
suggested by the concentration-dependent toxicity observed in the current study. 
Other factors reported in the literature suggested to increase the risk of liver toxicity 
include polydrug abuse and hyperthermia (Armenian et al., 2013; Borek and 
Holstege, 2012; Dias da Silva et al., 2013a; Dias da Silva et al., 2013b; Green et al., 
2004; Prosser and Nelson, 2012). CYP2D6 activity could also play a role, since, as 
discussed previously, the catechol metabolites of methylenedioxy cathinones (MDPV 
and methylone in the current study) may be more toxic than the respective parent 
compounds (Antolino-Lobo et al., 2011a; Carmo et al., 2006). CYP2D6 ultrarapid 
metabolizers may therefore be at risk for hepatotoxicity associated with these 
compounds. If mitochondrial dysfunction is a main toxicological mechanism, as 
suggested by the current study, also preexisting mitochondrial dysfunction may 
render patients more suceptible. This has been shown for severe hepatotoxicity 
induced by valproic acid, where preexisting mitochondrial dysfunction is an 
established suceptibility factor (Krahenbuhl et al., 2000; Stewart et al., 2010). 
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Blood concentrations determined in drug users or post mortem cases were 
typically lower than the toxic concentrations in our cellular assays (Cawrse et al., 
2012; Cosbey et al., 2013; Torrance and Cooper, 2010; Wikström et al., 2010). 
However, a case with post-mortem mephedrone blood concentrations >100 µM has 
been described (Torrance and Cooper, 2010) and in a series of methylone 
associated fatalities, drug concentrations in the liver were higher than in the blood, 
with an average liver-to-blood ratio of 2.68 (Cawrse et al., 2012). Moreover, HepG2 
cells appear to be more robust to toxicants than human hepatocytes (Gerets et al., 
2012) and the presence of suceptibility factors may shift the blood or liver 
concentration-toxicity curve to lower concentrations. 
In conclusion, our investigations give a closer insight into the mechanism of 
cathinone-induced hepatotoxicity and demonstrate that bupropion, MDPV, 
mephedrone and naphyrone are associated with mitochondrial dysfunction due to 
interactions with enzyme complexes of the electron transport chain. Since liver injury 
is rare in persons ingesting these compounds, users with liver injury have to have 
risk factors rendering them more suceptible. 
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Figure legends 
 
Fig. 1. Structures of the synthetic cathinones used in the study. 
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Fig. 2. Effect on the intracellular ATP content preceding cytotoxicity. 
Intracellular ATP content and cytotoxicity expressed as release of adenylate kinase 
after drug exposure for 24 h in HepG2 and non-induced HepaRG cells. Data are 
expressed as mean ± SEM of at least three independent experiments. Differences 
between control and test drugs were calculated with ANOVA followed by Dunett’s 
test. Significance levels for HepG2 cells are given as *p<0.05, **p<0.01, ***p<0.001. 
Significance levels for HepaRG cells are given as ##p<0.01, ###p<0.001. 
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Fig. 3. No effect on the intracellular ATP content preceding cytotoxicity. 
Intracellular ATP content and cytotoxicity expressed as release of adenylate kinase 
after drug exposure for 24 h in HepG2 and non-induced HepaRG cells. Data are 
expressed as mean ± SEM of at least three independent experiments. Differences 
between control and test drugs were calculated with ANOVA followed by Dunett’s 
test. Significance levels for HepG2 cells are given as *p<0.05, **p<0.01, ***p<0.001. 
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Fig. 4. Effect on mitochondrial membrane potential of HepG2 cells. 
Mitochondrial membrane potential after 24 h drug exposure expressed as mean ± 
SEM of at least three independent experiments compared to vehicle control. 
Differences between control and test drugs were calculated with ANOVA followed by 
Dunett’s test. Significance levels are given as **p<0.01, ***p<0.001. 
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Fig. 5. Function of the respiratory chain in HepG2 cells. 
Oxygen consumption rate (OCR) in HepG2 cells after 24 h drug exposure. Data are 
expressed as mean ± SEM of at least four independent experiments. Basal 
respiration, leak respiration, and maximal respiration were determined after drug 
treatment as specified in Methods and were compared to the respective vehicle 
control values. Statistical significance was calculated with ANOVA followed by 
Dunett’s test and significance levels are given as *p<0.05, **p<0.01, ***p<0.001. 
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Fig. 6. Effect on the activity of the enzyme complexes of the mitochondrial 
electron transport chain measured using the Oxygraph-2k-high-resolution 
respirometer in HepG2 cells. 
Respiratory capacities of HepG2 cells after 24 h treatment of bupropion (a, b), MDPV 
(c, d), mephedrone (e, f), and naphyrone (g, h). Data are expressed as mean ± SEM 
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of at least six independent experiments. Treatment was compared to vehicle control 
with an unpaired two-tailed Student's t-test. Significance levels are given as *p<0.05,  
**p<0.01, ***p<0.001. 
 
 
Fig. 7. Cellular stress and tGSH content in HepG2 cells 
Superoxide production, lactate concentrations and total GSH levels after 24 h drug 
treatment. Data are expressed as mean ± SEM of at least three independent 
experiments compared to vehicle control. Statistical significance was calculated with 
ANOVA followed by Dunett’s test and significance levels are given as *p<0.05, 
**p<0.01, ***p<0.001 for superoxide production and GSH and ##p<0.01, ###p<0.001 
for lactate production.
 
Table 1. Summary of the toxicity associated with the cathinones investigated. 
 Bupropion 
(mM) 
MDPV 
(mM) 
Mephedrone 
(mM) 
Methedrone 
(mM) 
Methylone 
(mM) 
Naphyrone 
(mM) 
HepaRG cells       
Cytotoxicity 2     1 
ATP depletion 1 2    1 
HepG2 cells       
Cytotoxicity 2 2 2 2 2 0.5 
ATP depletion 0.5 1 1 2  0.2 
Decrease of Δψm 0.5 1    0.2 
Superoxide production 0.5 2 1   0.2 
Lactate production 0.5 1 1   0.2 
GSH depletion  2    0.2 
Complex I disruption 0.5 1 1   0.2 
Complex II disruption 0.5 1 1   0.2 
Complex III disruption      0.2 
Complex IV disruption       
The concentrations (mM) indicated in the Table correspond to the lowest concentration where a significant 
toxic effect was recorded. The data are obtained from Fig. 2 to Fig. 7. Where no concentration is listed, no 
significant toxicity was observed in the concentration range investigated. 
 
